Fortis Healthcare to divest its Vadapalani, Chennai Hospital business operations to Kauvery Group of Hospitals

Biostar Pharma receives FDA approval Utidelone Injectable Phase 2/3 clinical trial for cell lung cancer

This trial is a multi-national, phase 2/3, open-label, randomized, controlled clinical study of utidelone injectable

Merck completes acquisition of Prometheus Biosciences

Acquisition delivers industry-leading research capability, and strengthens pipeline with a novel candidate for ulcerative colitis, Crohn’s disease and other autoimmune conditions

Biostar announces first patient enrolled for Phase 1 study of Utidelone Capsule

UTD2 is the world's first oral epothilone microtubule inhibitor

Zydus announces Phase IV EVIDENCES-XI trial to generate Real World Evidence of Saroglitazar Mg in NAFLD patients with comorbidities

The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52

Brinton appoints Amit Jain as President & Head of Domestic Business

Jain will have oversight of Brinton's domestic operations, including business development, sales, and marketing

Suven Life Sciences completes enrollment of patients to the phase-2, PoC clinical study of samelisant for the treatment of narcolepsy

Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada

Laurus Labs to increase stake in ImmunoACT to 33.86%

This fresh infusion of capital will enable ImmunoACT to fast track the additional supply of the lead candidate HCAR-19

Ind-Swift Laboratories reports FY23 PAT at Rs. 42.47 Cr

The company reported lifetime high EBIDTA of Rs. 250 crores

Hikal posts FY23 PAT at Rs. 36 Cr

Pharmaceutical sales was flat and stood at Rs. 309 crore as compared to Rs. 308 crore in Q4 FY22